Corbus Pharmaceuticals Holdings, Inc. (CRBP)
3.07
+0.21
(+7.34%)
USD |
NASDAQ |
Nov 06, 16:00
3.06
-0.01
(-0.33%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Research and Development Expense (Annual) : 70.10M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 70.10M |
| December 31, 2024 | 32.22M |
| December 31, 2023 | 31.17M |
| December 31, 2022 | 16.14M |
| December 31, 2021 | 36.45M |
| December 31, 2020 | 98.27M |
| December 31, 2019 | 94.19M |
| Date | Value |
|---|---|
| December 31, 2018 | 48.61M |
| December 31, 2017 | 26.04M |
| December 31, 2016 | 15.44M |
| December 31, 2015 | 5.889M |
| December 31, 2014 | 1.256M |
| December 31, 2013 | 0.2107M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Heron Therapeutics, Inc. | 12.43M |
| Tonix Pharmaceuticals Holding Corp. | 44.49M |
| Karyopharm Therapeutics, Inc. | 125.32M |
| Minerva Neurosciences, Inc. | 5.760M |
| Ocugen, Inc. | 37.36M |